9-21980152-A-G

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_058195.4(CDKN2A):​c.194-8944T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.886 in 152,198 control chromosomes in the GnomAD database, including 59,828 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.89 ( 59828 hom., cov: 32)

Consequence

CDKN2A
NM_058195.4 intron

Scores

2

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: -0.915

Publications

19 publications found
Variant links:
Genes affected
CDKN2A (HGNC:1787): (cyclin dependent kinase inhibitor 2A) This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
CDKN2A Gene-Disease associations (from GenCC):
  • melanoma, cutaneous malignant, susceptibility to, 2
    Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
  • melanoma-pancreatic cancer syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • familial atypical multiple mole melanoma syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • melanoma and neural system tumor syndrome
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.98).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.957 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CDKN2ANM_058195.4 linkc.194-8944T>C intron_variant Intron 1 of 2 ENST00000579755.2 NP_478102.2 Q8N726-1
CDKN2ANM_001363763.2 linkc.-3-8944T>C intron_variant Intron 1 of 2 NP_001350692.1
CDKN2AXM_047422597.1 linkc.-3-8944T>C intron_variant Intron 1 of 2 XP_047278553.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CDKN2AENST00000579755.2 linkc.194-8944T>C intron_variant Intron 1 of 2 1 NM_058195.4 ENSP00000462950.1 Q8N726-1

Frequencies

GnomAD3 genomes
AF:
0.886
AC:
134808
AN:
152080
Hom.:
59787
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.856
Gnomad AMI
AF:
0.905
Gnomad AMR
AF:
0.909
Gnomad ASJ
AF:
0.896
Gnomad EAS
AF:
0.980
Gnomad SAS
AF:
0.952
Gnomad FIN
AF:
0.904
Gnomad MID
AF:
0.870
Gnomad NFE
AF:
0.884
Gnomad OTH
AF:
0.892
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.886
AC:
134908
AN:
152198
Hom.:
59828
Cov.:
32
AF XY:
0.889
AC XY:
66100
AN XY:
74388
show subpopulations
African (AFR)
AF:
0.856
AC:
35526
AN:
41506
American (AMR)
AF:
0.910
AC:
13905
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
0.896
AC:
3107
AN:
3468
East Asian (EAS)
AF:
0.979
AC:
5075
AN:
5182
South Asian (SAS)
AF:
0.952
AC:
4582
AN:
4814
European-Finnish (FIN)
AF:
0.904
AC:
9581
AN:
10596
Middle Eastern (MID)
AF:
0.871
AC:
256
AN:
294
European-Non Finnish (NFE)
AF:
0.884
AC:
60165
AN:
68028
Other (OTH)
AF:
0.894
AC:
1886
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
778
1556
2335
3113
3891
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
900
1800
2700
3600
4500
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.888
Hom.:
52567
Bravo
AF:
0.886
Asia WGS
AF:
0.947
AC:
3295
AN:
3478

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.98
CADD
Benign
0.82
DANN
Benign
0.39
PhyloP100
-0.92
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs2811709; hg19: chr9-21980151; API